A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Launched by ELI LILLY AND COMPANY · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called bimagrumab, both on its own and combined with another medication called tirzepatide. The main goal is to see how these medications are absorbed and how they behave in the body. If you decide to participate, the study will last about 4.5 months, which includes a screening phase to check your health and a follow-up afterward.

To be eligible for this study, you need to be generally healthy, with a body mass index (BMI) between 22.0 and 30.0. However, if you have a history of certain health issues like pancreatitis or uncontrolled high blood pressure, or if you've recently lost or gained more than 5 kilograms in weight, you may not qualify. Participants will undergo medical evaluations to ensure they meet these criteria and will have the chance to contribute to important research that could help in understanding these medications better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Are considered healthy as determined by medical evaluation including medical history and physical examination
• • Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive
• Exclusion Criteria:
• • Have current or a history of pancreatitis or hepatitis
• • Have a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening
• • Have uncontrolled high blood pressure
• • Have taken medications or alternative remedies to promote weight loss within 3 months prior to screening